Protara Therapeutics, Inc.
TARA•NASDAQ•Healthcare•Biotechnology

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJesse Shefferman
Employees33
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.protaratx.com
Phone646 844 0337
Address
345 Park Avenue South, 3rd Floor New York, New York 10010 United States

Corporate Identifiers

CIK0001359931
CUSIP74365U107
ISINUS74365U1079
EIN20-4580525
SIC2836

Leadership Team & Key Executives

Jesse Shefferman
Co-founder, Chief Executive Officer, President and Director
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.
Co-Founder and Chief Scientific Operations Officer
Patrick Fabbio M.B.A.
Chief Financial Officer
Hannah Fry
Vice President, Principal Accounting Officer and Controller
Justine O'Malley
Senior Vice President of Investor Relations and Corporate Affairs
Mary J. Grendell J.D.
General Counsel and Corporate Secretary
Dr. Shane Williams Ph.D.
Chief People Officer
Dr. Leonardo Viana Nicacio M.D.
Chief Medical Officer
William Conkling
Chief Commercial Officer